logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Dec 2020
Kura Oncology Inc.
Preliminary data from Phase 1/2A clinical trial of KO-539 (KOMET-001)
Relapsed/refractory acute myeloid leukemia
Dec 2020
Corvus Pharmaceuticals, Inc.
Updated clinical data from Phase 1/1b clinical trial of CPI-818
Relapsed/Refractory T-Cell Lymphoma
Mid Nov 2020
Lineage Cell Therapeutics, Inc.
New data from Phase 1/2a trial of OpRegen
Dry age-related macular degeneration
Late Nov 2020
Brainstorm Cell Therapeutics Inc.
Top-line data from phase III pivotal trial of NurOwn
Amyotrophic lateral sclerosis
Q4 2020
IMARA Inc.
Top-line data from phase IIa clinical trial of IMR-687
Sickle cell disease in adults
Q4 2020
Arena Pharmaceutical Inc.
Topline data from phase 2b ADVISE trial evaluating etrasimod
Atopic dermatitis (AD)
Q4 2020
Arena Pharmaceutical Inc.
Topline data from Phase 1 trial of APD418
Acute heart failure (AHF)
Q4 2020
Inovio Pharmaceuticals Inc.
18-Month Overall Survival Data from phase II trial of INO-5401
Glioblastoma multiforme
Q4 2020
Otonomy Inc.
Results from phase I/II clinical trial of OTO-413
Hearing loss
Q4 2020
Hepion Pharmaceuticals, Inc.
Results from phase IIa trial of CRV431 (AMBITION)
NASH fibrosis
Q4 2020
Palatin Technologies Inc.
Data readout from Phase 2 clinical study of PL9643
Dry eye disease (DED)
Q4 2020
Aurinia Pharmaceuticals Inc.
AUPH, AUP.V
Data from phase II/III trial of Voclosporin (AUDREY)
Dry eye syndrome
Q4 2020
Aileron Therapeutics, Inc.
Final phase 1b dose optimization data of ALRN-6924
Chemotherapy-induced bone marrow toxicities
Q4 2020
Kiniksa Pharmaceuticals, Ltd.
Data from global Phase 2 trial of Mavrilimumab
Giant cell arteritis
Q4 2020
Kiniksa Pharmaceuticals, Ltd.
Data from a single-ascending-dose Phase 1 trial of KPL-404 in healthy volunteers
Severe autoimmune diseases
Q4 2020
Inventiva S.A
End of Phase IIb meetings related to Lanifibranor
NASH
Q4 2020
Kadmon Holdings LLC
Submit NDA for Belumosudil
Chronic graft-versus-host disease
Q4 2020
Ligand Pharmaceuticals Inc
Topline data from phase 2/3 study of PTX-022 (VALO)
Pachyonychia congenita (PC).
Q4 2020
MacroGenics Inc.
Updated data from Phase 1/2 study of Flotetuzumab
Acute myeloid leukemia
Q4 2020
Mirum Pharmaceuticals Inc.
Submission of MAA to European regulators for Maralixibat
Progressive Familial Intrahepatic Cholestasis
Q4 2020
Arcus Biosciences, Inc
Mature Phase 1b data of AB928
Multiple tumor types
Q4 2020
Arcus Biosciences, Inc
Early Phase 2 randomized data of AB928
Multiple tumor types
Q4 2020
Arcus Biosciences, Inc
Randomized data from phase II study of AB154
First-line NSCLC
Q4 2020
Inovio Pharmaceuticals Inc.
Top-line efficacy data from phase III trial of VGX-3100 (REVEAL 1)
Cervical dysplasia caused by human papillomavirus (HPV)
Q4 2020
Inovio Pharmaceuticals Inc.
18-month overall survival data from phase II trial of INO-5401
Glioblastoma multiforme